<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92266">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723254</url>
  </required_header>
  <id_info>
    <org_study_id>B4901001</org_study_id>
    <nct_id>NCT01723254</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis</brief_title>
  <official_title>A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-IgE Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of different doses of
      PF-06444753 and PF-06444752 in subjects with allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Local reactogenicity events</measure>
    <time_frame>Within 14 days after dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency of local reactogenicity events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic reactogenicity events</measure>
    <time_frame>Within 14 days after dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency of systemic reactogenicity events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 336</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.  An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal safety laboratory findings</measure>
    <time_frame>Baseline up to Day 336</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>blood chemistry, hematology, coagulation, and urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titers against IgE</measure>
    <time_frame>Baseline up to Day 336</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers against IgE</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>PF-06444753</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06444752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGE-1</intervention_name>
    <description>Intramuscular, multiple dose</description>
    <arm_group_label>PF-06444753</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGE-2</intervention_name>
    <description>Intramuscular, multiple dose</description>
    <arm_group_label>PF-06444752</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline (0.9% sodium chloride)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, males or females of non-child bearing potential, who are between 18 and 55
             years, inclusive,

          -  Intermittent or persistent allergic rhinitis that is associated with perennial or
             seasonal allergen reactivity at screening as determined by a positive specific IgE
             level â‰¥1 KU/L to at least one of the following common allergens: dust mite
             (Dermatophagoides farinae or Dermatophagoides pteronyssinus), cat, dog, mold
             (Alternaria), Bermuda grass, common ragweed, oak, Timothy grass or elm.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic
             disease that may compromise their ability to safely participate in the study.

          -  Evidence or history of clinically significant pulmonary disease (including allergic
             and non-allergic asthma, chronic obstructive pulmonary disease [COPD], cystic
             fibrosis, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary
             fibrosis, pulmonary hypertension, or others).

          -  Evidence or history of clinically significant autoimmune disease (including
             rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, or others).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 3C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4901001&amp;StudyName=A%20Study%20To%20Assess%20The%20Safety%20And%20Tolerability%20Of%20Different%20Doses%20Of%20PF-06444753%20And%20PF-06444752%20In%20Subjects%20With%20Allergic%20Rhinitis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Allergic Rhinitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
